Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid vs standard treatment in adult Omicron COVID-19 (Shijiazhuang)
ChiCTR2300071537Phase 4Recruiting
- Sponsor
- Shijiazhuang People's Hospital
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shijiazhuang People's Hospital. Primary endpoints: Time of first nucleic acid negative, Time to two consecutive nucleic acid negatives and 3 more. Started Nov 2022; status: recruiting.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300071537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071537.